Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05642858 · ClinicalTrials.gov registry record · NA

Text Education About Cardiovascular Health and HIV (TEACH-HIV)

A NA study of HIV and Cardiovascular Diseases, sponsored by University of California, San Francisco.

Recruiting
Registry status
NA
Development phase
260
Enrollment target
2
Study locations

NCT05642858 is a NA study of HIV and Cardiovascular Diseases that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 260 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (41% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05642858, a NA study of HIV and Cardiovascular Diseases, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
NA
Development phase
260 participants
Enrollment target
2
Study locations

Study Summary

The overall objective is to evaluate the efficacy of educational text messages to reduce cardiovascular risk among persons living with HIV (PLWH).

Interventions

  • BEHAVIORAL Digital Educational Messaging

Study Locations (2)

California

  • Zuckerberg San Francisco General Hospital - San Francisco
  • University of California San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 260 participants
Start Date 2023-03-12
Est. Completion 2026-07-01
Phase NA

What the Registry Record Tells You About NCT05642858

The ClinicalTrials.gov registry entry for NCT05642858 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 439-participant average among 303 other HIV trials with a reported enrollment target (41% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Digital Educational Messaging is the first listed.

NCT05642858 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05642858 about?

NCT05642858 is a clinical study titled "Text Education About Cardiovascular Health and HIV (TEACH-HIV)". The overall objective is to evaluate the efficacy of educational text messages to reduce cardiovascular risk among persons living with HIV (PLWH).

What is the current status of trial NCT05642858?

This trial is currently recruiting. It is a NA study. The enrollment target is 260 participants. The study started on 2023-03-12. Estimated completion is 2026-07-01.

What conditions does trial NCT05642858 study?

This clinical trial studies the following conditions: HIV, Cardiovascular Diseases, Atherosclerosis, Human Immunodeficiency Virus.

What interventions are being tested in trial NCT05642858?

The interventions under investigation include: Digital Educational Messaging (BEHAVIORAL).

Who is sponsoring clinical trial NCT05642858?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05642858 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.